Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 5/20 | 0.51 |
| ▸ | HTR1A | P08908 | 2/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.48 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | KHK | P50053 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23057958 | 0.86 | KDM4E (0.48) | NISCHKDM4EL3MBTL1TSHRHTT | |
| SCHEMBL22838553 | 0.86 | KDM4E (0.48) | HRH1HTR1ANISCHKDM4EL3MBTL1 | |
| SCHEMBL10267024 | 0.84 | HRH1 (0.57) | HRH1HTR1ASLC6A2SLC6A3NISCH | |
| SCHEMBL4247388 | 0.78 | HRH1 (0.57) | HRH1HTR1ASLC6A2SLC6A3KDM4E | |
| SCHEMBL19021076 | 0.77 | PDE4D (0.46) | NISCHKDM4EL3MBTL1TSHRHTT | |
| SCHEMBL3606028 | 0.76 | LMNA (0.44) | HRH1KDM4EL3MBTL1HTT | |
| SCHEMBL22435586 | 0.75 | PDE4A (0.40) | HTR1AKDM4EL3MBTL1HTT | |
| SCHEMBL1780546 | 0.73 | HRH1 (0.62) | HRH1HTR1ASLC6A2SLC6A3SLC6A4 | |
| SCHEMBL1229562 | 0.73 | HRH1 (0.62) | HRH1HTR1ASLC6A2SLC6A3SLC6A4 | |
| SCHEMBL22871103 | 0.72 | ADRA2A (0.44) | HRH1HTR1ASLC6A2SLC6A3NISCH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100004245-A1 | AZACYCLOALKANE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK FROSST CANADA LTD. (CA) | 2010-01-07 | — | — | US | disclosed |
| EP-2076509-A1 | AZACYCLOALKANE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | Merck Frosst Canada Ltd. (CA) | 2009-07-08 | — | — | EP | disclosed |
| WO-2008046226-A1 | AZACYCLOALKANE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK FROSST CANADA LTD. (CA) | 2008-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004245-A1 | AZACYCLOALKANE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | SCD, SCD5, SREBF1 | HRH1 4142/4885HTR1A 3310/4885SLC6A2 4725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.